Heart Rate Control Before Cardiac Computed Tomography in Adults for the Evaluation of Coronary Artery Disease

Summary

The goal of this clinical trial is to describe which type and dose of commonly used heart rate reducing drugs (metoprolol, atenolol, or ivabradine) has the swiftest heart rate reduction from baseline in patients aged 30 to 80 years with a heart rate \> 65 beats per minute undergoing cardiac computed tomography for the evaluation of coronary artery disease. The main question it aims to answer is

• Which type of heart reducing drug and dose has the swiftest heart rate reduction before cardiac computed tomography?

Conditions

• Coronary Arterial Disease (CAD)
• Ischemic Heart Disease (IHD)

Interventions

DRUG

Atenolol/Metoprolol tartrate

No studies have compared metoprololtartrat, ivabradine, atenolol and placebo in different doses as drugs before cardiac computed tomography

DRUG

Ivabradine 7.5/15 mg

No studies have compared metoprololtartrat, ivabradine, atenolol and placebo in different doses as drugs before cardiac computed tomography

DRUG

Ivabradine

No studies have compared metoprololtartrat, ivabradine, atenolol and placebo in different doses as drugs before cardiac computed tomography

DRUG

atenolol

No studies have compared metoprololtartrat, ivabradine, atenolol and placebo in different doses as drugs before cardiac computed tomography

DRUG

Metoprolol tartrate

No studies have compared metoprololtartrat, ivabradine, atenolol and placebo in different doses as drugs before cardiac computed tomography

Sponsors & Collaborators

• Department of Cardiology, Gødstrup Hospital, Herning, Denmark

  collaborator UNKNOWN

• Gødstrup Hospital

  lead OTHER

Principal Investigators

• Morten Böttcher, Professor · University Clinic of Ishemic Heart Disease, Gødstrup Hospital

• Simon Winther, MD, PhD · University Clinic of Ishemic Heart Disease, Gødstrup Hospital

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Model

PARALLEL

Eligibility

Min Age

30 Years

Max Age

80 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2025-12-15

Primary Completion

2028-09-01

Completion

2028-09-30

Countries

• Denmark

Study Locations